-
The new Pharmacopoeia Committee was established, and the preparation of the 2025 edition of the Chinese Pharmacopoeia was launched
Time of Update: 2022-10-12
It is necessary to continuously improve the scientificity, advancedness, practicality and standardization of pharmacopoeia, and strengthen the guiding role of the Chinese Pharmacopoeia in ensuring the safety, effectiveness and quality control of drugs; Implement the concept of drug life cycle management, actively explore the development strategy of drug standards, give full play to the important technical support role of drug standards for drug supervision, and promote the improvement of regulatory capabilities.
-
Drug treatment of lower gastrointestinal bleeding, these need to be paid attention
Time of Update: 2022-10-01
First of all, according to the patient's vital signs, the degree of circulating volume deprivation, bleeding rate, age and complications, establish an effective intravenous access (deep venous catheterization), and give appropriate hemostasis, rehydration, blood transfusion and other treatments to maintain the stability of vital signs and prevent complications.
-
CDE publishes "Technical Guidelines for Clinical Pharmacology Research of Biosimilars
Time of Update: 2022-03-08
Clinical pharmacology research is an important part of the comparison study of biosimilars, and it is very important to support the similarity evaluation of the efficacy and safety of biosimilars and reference drugs .
Attachment: Technical Guidelines for Clinical Pharmacology Research of Biosimilars.
-
Junshi Biological Appoints Dr. Virginia Ellen Maher as Vice President of Medical Sciences
Time of Update: 2021-12-09
Maher worked in the US Food and Drug Administration (FDA) for nearly 20 years, serving as a clinical reviewer of the Office of Oncology Products, and a clinical review team of the Office of Cell, Tissue and Gene Therapy of the Center for Biologics Evaluation and Research (CBER) Chief, the clinical review team leader of the Office of Hematology and Tumor Products of the Center for Drug Evaluation and Research (CDER) .
-
Lumasiran is proven to be safe and effective again | patients with rare disease PH1 are expected to bid farewell to liver and kidney transplantation
Time of Update: 2021-06-11
In the Phase 2 clinical trial, the oxalic acid excretion of all 20 patients in the Lumasiran group was ≤0.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
-
After four price cuts, Sharp Ass finally divested its proprietary Chinese medicine business for 82 million yuan
Time of Update: 2021-05-02
This is a decrease of 58% from the initial listing price of 195 million yuan, which is a far cry from the initial investment of 481 million yuan when Sharp Aisi acquired Qiangshen Pharmaceutical.
-
Health care products chaos repeatedly banned more than the market will usher in high-frequency rectification
Time of Update: 2021-02-05
An industry insider, who did not want to be named, said that the focus of the health care industry consolidation will still be placed on these two aspects, the future rectification will also be extended to health food licensing qualifications, product quality and safety, advertising, Internet operations and illegal marketing.
-
The pharmacy checked before the National Day
Time of Update: 2020-09-30
Retail pharmacies (including chain pharmacies) for daily purchase of anti-heat, cough, antiviral, antibiotics and other drugs, all must be registered with real-name information (registration form samples are attached), and the above-mentioned drug sales dynamic monitoring, in accordance with the market supervision bureau clear reporting channels and requirements, daily reporting to the local market supervision bureau.
-
Twenty practicing pharmacists were investigated
Time of Update: 2020-09-11
On August 10, the Guangdong Provincial Drug Administration issued a circular on the inspection of the "registered" behavior of practicing pharmacists in pharmaceutical enterprises (No. 67 of 2020).
-
FDA approves new drug for advanced kidney cancer
Time of Update: 2020-07-08
the U.S Food and Drug Administration approved a new drug Wednesday to extend the survival of patients with advanced kidney cancer The drug, called Torisel, is manufactured by Wyeth Pharmaceuticals
-
China's State Drug Administration approves Gilead compound preparation bitovi® (Biken pronosis) for the treatment of HIV-1 virus infection
Time of Update: 2020-06-08
Recently, Gilead Sciences (NASDAQ: GILD) announced that its daily service mono-combination formulation, the Pitutovi ® (Biken pronotablets), has been approved by China's National Medicines (http:/
-
China's State Drug Administration approves clinical trial application for Skyland Bio TJM2
Time of Update: 2020-06-07
Recently, Tianyuan Biotech (Shanghai) Limited Company (http:// ("Tianyuan Bio") announced that China's National Pharmaceutical (http:// Regulatory Authority has approved the tJM2 Clinical Tes
-
The digital wave hits, pharmaceutical companies start to try a new promotion model
Time of Update: 2020-05-30
Pharmaceutical network May 28th, the digital wave hit, the growth rate of the pharmaceutical retail industry slowed down, store passenger flow showed a downward trend Where are the new marketing chan
-
Nine provinces joint supplies negotiations 19 proposed pick-up equipment enterprises list announced
Time of Update: 2020-05-21
Medical Network May 21 hearing May 18, Beijing, Tianjin and medical supplies procurement platform jointly issued the "Beijing, Tianjin and Liaoning and Heilongjiang and Jilin Mongolia, Shanxi, Shandon
-
Implementation of major policies affects all pharmaceutical enterprises
Time of Update: 2020-01-03
For all pharmaceutical companies, the layout of drug traceability is a must to do thing, only in advance to seize the opportunity, in order to be invincible in the competition On December 1, the new v
